Caris Life Sciences Q3 net income drops 37% to $15.25 million; Q3 revenue rises 27% to $275.36 million

By Public Technologies
  • Caris Life Sciences' third-quarter 2026 net income fell 37% to $15.25 million, while revenue rose 27% to $275.4 million.
  • Operating cash flow swung to an outflow of $22.2 million, due to commercial expansion, inventory buildup and research investment.
  • Clinical cases climbed approximately 21% year over year to approximately 61,500.
  • Caris Assure launched treatment-response monitoring, while the Caris Confirm minimal residual disease assay remains targeted for launch before year-end.
  • Full-year 2026 revenue guidance increased to $1.04 billion–$1.05 billion, representing growth of 28%–29%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA88569) on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.